KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Other Operating Expenses (2017 - 2025)

Moderna (MRNA) has disclosed Other Operating Expenses for 8 consecutive years, with $452.0 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 38.84% to $452.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $868.0 million through Dec 2025, down 40.71% year-over-year, with the annual reading at $868.0 million for FY2025, 40.71% down from the prior year.
  • Other Operating Expenses for Q4 2025 was $452.0 million at Moderna, up from $207.0 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $2.2 billion in Q3 2023, with the low at $90.0 million in Q1 2025.
  • Average Other Operating Expenses over 5 years is $752.9 million, with a median of $735.0 million recorded in 2023.
  • The sharpest move saw Other Operating Expenses soared 11800.0% in 2021, then crashed 87.88% in 2024.
  • Over 5 years, Other Operating Expenses stood at $952.0 million in 2021, then surged by 101.47% to $1.9 billion in 2022, then tumbled by 51.56% to $929.0 million in 2023, then decreased by 20.45% to $739.0 million in 2024, then plummeted by 38.84% to $452.0 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $452.0 million, $207.0 million, and $119.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.